Fig. 5From: Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker studyPotential tissue-based predictive biomarkers of response to sintilimab plus docetaxel therapy. Low PD-L1/High-CD8 expression in pre-treatment tissue samples was associated with higher objective response rate (A), but no significant difference in progression-free survival (PFS) and overall survival time (C)Back to article page